Growth hormone deficiency - adult patients

The Pharmaceutical Benefits Scheme (PBS) subsidises somatropin for adult patients with severe growth hormone deficiency.

Patient eligibility

The PBS subsidises treatment with somatropin under the National Health Act 1953, section 100 - Growth Hormone Program, for adult patients with severe growth hormone deficiency.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing somatropin.

Treatment specifics

Patients must be treated by an endocrinologist for initial treatment and by or in consultation with an endocrinologist for continuing treatment to be eligible for PBS subsidised treatment with somatropin.

Applications

Initial treatment

Apply for initial authority approval to prescribe PBS subsidised somatropin for severe growth hormone deficiency in writing and either:

All applications must include the completed:

Continuing treatment

Apply for authority approval to continue PBS subsidised somatropin to treat severe growth hormone deficiency in writing and either:

All applications must include the completed:

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 22 February 2019

Was this page useful?
Why?
Why not?

Thank you for your feedback.